Пређи на садржај

SB-742,457 — разлика између измена

С Википедије, слободне енциклопедије
Интерактиван преглед историје
← Старија измена
Садржај обрисан Садржај додат
ВизуелноВикитекст
м .
м normativna kontrola
 
(Није приказана једна међуизмена другог корисника)
Ред 35: Ред 35:
}}
}}


'''-{SB}--742,457''' je [[selektivnost vezivanja|selektivni]] [[antagonist (farmakologija)|antagonist]] [[5-HT6 receptor|5--{HT}-<sub>6</sub> receptora]] sa uticajem na [[kognicija|kogniciju]], [[memorija|memoriju]], i [[učenje]].<ref name="pmid18625457">{{cite journal |vauthors=Upton N, Chuang TT, Hunter AJ, Virley DJ | title = 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease | journal = Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics | volume = 5 | issue = 3 | pages = 458–69 | year = 2008 | pmid = 18625457 | doi = 10.1016/j.nurt.2008.05.008 | url = http://linkinghub.elsevier.com/retrieve/pii/S1933-7213(08)00100-1}}</ref><ref name="pmid19851757">{{cite journal |author1=Idris N |author2=Neill J |author3=Grayson B |author4=''et al.'' | title = Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms | journal = Psychopharmacology | volume = 208 | issue = 1 | pages = 23–36 | year = 2010 | pmid = 19851757 | doi = 10.1007/s00213-009-1702-5 }}</ref><ref name="pmid20043816">{{cite journal |author1=Maher-Edwards G |author2=Zvartau-Hind M |author3=Hunter AJ |author4=''et al.'' |title=Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease |journal=Current Alzheimer Research |volume=7 |issue=5 |pages=374–85 |year=2009 |pmid=20043816 |doi= |url=http://www.benthamdirect.org/pages/epub/epinq.php?20043816 |access-date=12. 12. 2012 |archive-url=https://web.archive.org/web/20111006102116/http://www.benthamdirect.org/pages/epub/epinq.php?20043816 |archive-date=06. 10. 2011 |url-status=dead |df= }}</ref><ref name="pmid20166958">{{cite journal| vauthors = Rossé G, Schaffhauser H| title = 5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment| journal = Current Topics in Medicinal Chemistry| volume = 10| issue = 2| pages = 207–21| year = 2010| pmid = 20166958| doi = 10.2174/156802610790411036| url = http://www.benthamdirect.org/pages/epub/epinq.php?20166958| access-date = 12. 12. 2012| archive-url = https://web.archive.org/web/20111006102143/http://www.benthamdirect.org/pages/epub/epinq.php?20166958| archive-date = 06. 10. 2011|url-status=dead| df = }}</ref> On je u razvoju za tretman [[Alchajmerova bolest|Alchajmerove bolesti]] i preliminarno je pokazano da je efikasan u [[kliničko ispitivanje|kliničkim ispitivanjima]] faze II.<ref name="pmid20043816"/><ref name="pmid20166958"/><ref name="urlSearch of: SB-742457 - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=SB-742457 | title = Search of: SB-742457 - List Results - ClinicalTrials.gov | format = | work = | accessdate = }}</ref>
'''-{SB}--742,457''' je [[selektivnost vezivanja|selektivni]] [[antagonist (farmakologija)|antagonist]] [[5-HT6 receptor|5--{HT}-<sub>6</sub> receptora]] sa uticajem na [[kognicija|kogniciju]], [[memorija|memoriju]], i [[učenje]].<ref name="pmid18625457">{{cite journal |vauthors=Upton N, Chuang TT, Hunter AJ, Virley DJ | title = 5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease | journal = Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics | volume = 5 | issue = 3 | pages = 458–69 | year = 2008 | pmid = 18625457 | doi = 10.1016/j.nurt.2008.05.008 | url = http://linkinghub.elsevier.com/retrieve/pii/S1933-7213(08)00100-1}}</ref><ref name="pmid19851757">{{cite journal |author1=Idris N |author2=Neill J |author3=Grayson B |author4=''et al.'' | title = Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms |url=https://archive.org/details/sim_psychopharmacology_2010-01_208_1/page/23 | journal = Psychopharmacology | volume = 208 | issue = 1 | pages = 23–36 | year = 2010 | pmid = 19851757 | doi = 10.1007/s00213-009-1702-5 }}</ref><ref name="pmid20043816">{{cite journal |author1=Maher-Edwards G |author2=Zvartau-Hind M |author3=Hunter AJ |author4=''et al.'' |title=Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease |journal=Current Alzheimer Research |volume=7 |issue=5 |pages=374–85 |year=2009 |pmid=20043816 |doi= |url=http://www.benthamdirect.org/pages/epub/epinq.php?20043816 |access-date=12. 12. 2012 |archive-url=https://web.archive.org/web/20111006102116/http://www.benthamdirect.org/pages/epub/epinq.php?20043816 |archive-date=06. 10. 2011 |url-status=dead |df= }}</ref><ref name="pmid20166958">{{cite journal| vauthors = Rossé G, Schaffhauser H| title = 5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment| journal = Current Topics in Medicinal Chemistry| volume = 10| issue = 2| pages = 207–21| year = 2010| pmid = 20166958| doi = 10.2174/156802610790411036| url = http://www.benthamdirect.org/pages/epub/epinq.php?20166958| access-date = 12. 12. 2012| archive-url = https://web.archive.org/web/20111006102143/http://www.benthamdirect.org/pages/epub/epinq.php?20166958| archive-date = 06. 10. 2011|url-status=dead| df = }}</ref> On je u razvoju za tretman [[Alchajmerova bolest|Alchajmerove bolesti]] i preliminarno je pokazano da je efikasan u [[kliničko ispitivanje|kliničkim ispitivanjima]] faze II.<ref name="pmid20043816"/><ref name="pmid20166958"/><ref name="urlSearch of: SB-742457 - List Results - ClinicalTrials.gov">{{cite web | url = http://clinicaltrials.gov/ct2/results?term=SB-742457 | title = Search of: SB-742457 - List Results - ClinicalTrials.gov | format = | work = | accessdate = }}</ref>


== Reference ==
== Reference ==
Ред 45: Ред 45:
{{-}}
{{-}}
{{Serotonergici-lat}}
{{Serotonergici-lat}}

{{normativna kontrola}}


[[Категорија:Хинолини]]
[[Категорија:Хинолини]]

Тренутна верзија на датум 13. јануар 2024. у 19:46

SB-742,457
IUPAC ime
3-fenilsulfonil-8-(piperazin-1-il)hinolin
Klinički podaci
Način primeneOralno
Pravni status
Pravni status
  • Nije kontrolisan
Identifikatori
CAS broj607742-69-8 ДаY
ATC kodnone
PubChemCID 11256720
ChEMBLCHEMBL1083390 ДаY
Hemijski podaci
FormulaC19H19N3O2S
Molarna masa353,44 g/mol
  • C3CNCCN3c1cccc(c1nc4)cc4S(=O)(=O)c2ccccc2

SB-742,457 je selektivni antagonist 5-HT6 receptora sa uticajem na kogniciju, memoriju, i učenje.[1][2][3][4] On je u razvoju za tretman Alchajmerove bolesti i preliminarno je pokazano da je efikasan u kliničkim ispitivanjima faze II.[3][4][5]

Reference

[уреди | уреди извор]
  1. ^ Upton N, Chuang TT, Hunter AJ, Virley DJ (2008). „5-HT6 receptor antagonists as novel cognitive enhancing agents for Alzheimer's disease”. Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics. 5 (3): 458—69. PMID 18625457. doi:10.1016/j.nurt.2008.05.008. 
  2. ^ Idris N; Neill J; Grayson B; et al. (2010). „Sertindole improves sub-chronic PCP-induced reversal learning and episodic memory deficits in rodents: involvement of 5-HT(6) and 5-HT (2A) receptor mechanisms”. Psychopharmacology. 208 (1): 23—36. PMID 19851757. doi:10.1007/s00213-009-1702-5. 
  3. ^ а б Maher-Edwards G; Zvartau-Hind M; Hunter AJ; et al. (2009). „Double-Blind, Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-742457, in Alzheimer's Disease”. Current Alzheimer Research. 7 (5): 374—85. PMID 20043816. Архивирано из оригинала 06. 10. 2011. г. Приступљено 12. 12. 2012. 
  4. ^ а б Rossé G, Schaffhauser H (2010). „5-HT(6) Receptor Antagonists as Potential Therapeutics for Cognitive Impairment”. Current Topics in Medicinal Chemistry. 10 (2): 207—21. PMID 20166958. doi:10.2174/156802610790411036. Архивирано из оригинала 06. 10. 2011. г. Приступљено 12. 12. 2012. 
  5. ^ „Search of: SB-742457 - List Results - ClinicalTrials.gov”. 

Spoljašnje veze

[уреди | уреди извор]
Преузето из „https://sr.wikipedia.org/w/index.php?title=SB-742,457&oldid=26783389”